

Add claims 26-80 as follows:

Sub B' 7  
--26. A solvent vehicle, comprising a pharmaceutically acceptable dipolar aprotic solvent and a pharmaceutically acceptable aqueous secondary solvent.

A2  
27. The composition of claim 26, wherein said aprotic solvent comprises N,N-dimethylacetamide, castor oil, dimethylsulfoxide, 1,2,-propylene-diol, glycerol or polyethylene glycol-400.

28. The solvent vehicle of claim 27, wherein said aprotic solvent comprises N,N-dimethylacetamide.

29. The solvent vehicle of claim 27, wherein said aprotic solvent comprises castor oil.

30. The solvent vehicle of claim 27, wherein said aprotic solvent comprises dimethylsulfoxide.

31. The solvent vehicle of claim 27, wherein said aprotic solvent comprises 1,2,-propylene-diol.

32. The solvent vehicle of claim 27, wherein said aprotic solvent comprises glycerol.

33. The solvent vehicle of claim 27, wherein said aprotic solvent comprises polyethylene glycol-400.

Sub B2  
34. The composition of claim 26, wherein said secondary solvent comprises aqueous lipid emulsion, water, saline solution, dextrose solution, glacial acetic acid, lipid solution or parenteral infusion fluids.

35. The solvent vehicle of claim 34, wherein said secondary solvent comprises an aqueous lipid emulsion.

Sub B3  
36. The solvent vehicle of claim 35, wherein said aqueous lipid emulsion comprises Liposyn II™.

1A2  
37. The solvent vehicle of claim 35, wherein said aqueous lipid emulsion comprises an aqueous soy bean lipid emulsion.

Sub B4  
38. The solvent vehicle of claim 37, wherein said aqueous soy bean lipid emulsion comprises Intralipid™.

39. The solvent vehicle of claim 35, wherein said aqueous lipid emulsion comprises a lipid component that includes at least one vegetable oil and at least one fatty acid.

40. The solvent vehicle of claim 39, wherein said lipid component comprises at least about 5% by weight soybean oil and at least about 50% by weight fatty acids.

41. The solvent vehicle of claim 34, wherein said said secondary solvent comprises water.

42. The solvent vehicle of claim 34, wherein said secondary solvent comprises saline solution.

43. The solvent vehicle of claim 34, wherein said secondary solvent comprises dextrose solution.

44. The solvent vehicle of claim 43, wherein said dextrose solution comprises 5% to 70% dextrose in water.

45. The solvent vehicle of claim 44, wherein said dextrose solution comprises 5% or 10% dextrose solution.

46. The solvent vehicle of claim 34, wherein said secondary solvent comprises glacial acetic acid.

47. The solvent vehicle of claim 26, wherein said secondary solvent comprises a lipid solution.

48. The solvent vehicle of claim 26, wherein said secondary solvent comprises parenteral infusion fluids.

Sub 25  
contd

49. The solvent vehicle of claim 26, wherein said composition further comprises an active agent, a drug, pharmaceutically acceptable carriers, adjuvants or biologically active substances.

50. The solvent vehicle of claim 26, wherein said solvent vehicle comprises anhydrous N,N-dimethylacetamide and polyethylene glycol-400.

51. The solvent vehicle of claim 26, wherein said solvent vehicle comprises glacial acetic acid and polyethylene glycol-400.

52. The solvent vehicle of claim 26, wherein said solvent vehicle comprises anhydrous N,N-dimethylacetamide and aqueous lipid.

53. The solvent vehicle of claim 52, wherein said aqueous lipid is Intralipid™.

54. The solvent vehicle of claim 53, wherein said solvent vehicle comprises anhydrous N,N,-dimethylacetamide and Intralipid™ in a 1:10 volume ratio.

55. The solvent vehicle of claim 53, wherein said solvent vehicle comprises anhydrous N,N,-dimethylacetamide diluted with 9 volumes 20% Intralipid™.

56. The solvent vehicle of claim 53, wherein said solvent vehicle further comprises normal saline or 5% dextrose solution.

57. The solvent vehicle of claim 26, wherein said solvent vehicle comprises anhydrous N,N-dimethylacetamide, polyethylene glycol-400 and 1,2-propylene diol.

58. The solvent vehicle of claim 26, wherein said solvent vehicle comprises anhydrous N,N-dimethylacetamide, polyethylene glycol-400, 1,2-propylene diol and dimethylsulfoxide.

59. The solvent vehicle of claim 58, wherein said solvent vehicle comprises anhydrous N,N-dimethylacetamide, polyethylene glycol-400, 1,2-propylene diol and dimethylsulfoxide in equal volume ratios.

60. The solvent vehicle of claim 26, wherein said vehicle comprises glacial acetic acid, and wherein said vehicle further comprises anhydrous N,N-dimethylacetamide, dimethylsulfoxide or Intralipid™.

61. The solvent vehicle of claim 26, wherein said solvent vehicle comprises glacial acetic acid, dimethylsulfoxide and Intralipid™.

62. The solvent vehicle of claim 61, wherein said solvent vehicle comprises glacial acetic acid, dimethylsulfoxide, and Intralipid™ in a 2:6:3 volume ratio.

63. The solvent vehicle of claim 26, wherein said composition is administered to an animal.

64. The solvent vehicle of claim 26, wherein said composition is administered to a human.

65. The solvent vehicle of claim 26, wherein said composition is administered by parenteral injection.

66. The method of claim 65, wherein said parenteral injection is intravascular or intravenous injection.

67. The solvent vehicle of claim 26, wherein said composition is administered as an aerosol.

68. The solvent vehicle of claim 26, wherein said vehicle is lyophilized.

69. A composition, comprising a drug, a pharmaceutically acceptable dipolar aprotic solvent and a pharmaceutically acceptable aqueous secondary solvent.

70. The composition of claim 69, wherein said aprotic solvent comprises N,N-dimethylacetamide, castor oil, dimethylsulfoxide, 1,2,-propylene-diol, glycerol or polyethylene glycol-400.

71. The composition of claim 69, wherein said secondary solvent comprises aqueous lipid emulsion, water, saline solution, dextrose solution, glacial acetic acid, lipid solution or parenteral infusion fluids.

72. The composition of claim 69, wherein said composition has been lyophilized.
73. The composition of claim 69, wherein said composition further comprises a pharmaceutically acceptable aqueous solvent.
74. The composition of claim 73, wherein said aqueous solvent comprises a parenteral infusion fluid.
75. The composition of claim 74, wherein said parenteral infusion fluid is saline solution, dextrose solution or distilled water.
76. The composition of claim 73, wherein said aqueous solvent is suitable for parenteral administration to a mammal.
77. The composition of claim 76, wherein said mammal is a human.
78. A composition, comprising a pharmacologically active agent, a pharmaceutically acceptable dipolar aprotic solvent and a pharmaceutically acceptable aqueous secondary solvent.
79. The composition of claim 78, wherein said aprotic solvent comprises N,N-dimethylacetamide, castor oil, dimethylsulfoxide, 1,2,-propylene-diol, glycerol or polyethylene glycol-400.